Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Cyanoacrylate Closure for Treatment of Venous Leg Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04011371
Recruitment Status : Active, not recruiting
First Posted : July 8, 2019
Last Update Posted : May 18, 2022
Medtronic Vascular
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre

Brief Summary:
Venous leg ulcers (VLUs) are a common wound with significant morbidity and cost, and suboptimal therapeutic options. VLUs result from chronic venous insufficiency, including venous reflux and post-thrombotic syndrome. VLU can take from months to years to heal, and 54-78% recur. Current therapies include wound, compression therapy, and medications. These treatments can increase the rate of healing, and reduce recurrence, however these therapies can be burdensome, painful, and ineffective, and despite these therapies, ~50% of wounds become chronic. Chronic VLUs can be painful, malodorous, and infected, and they often significantly limit an individual's function and mobility. An emerging therapy for symptomatic venous reflux is the closure of the culprit vein by endovenous closure with a cyanoacrylate adhesive implant. Recent studies show cyanoacrylate closure (CAC) to be a safe and effective treatment for varicosities resulting from symptomatic incompetent great saphenous veins. This study will evaluate the safety and effectiveness of CAC for VLUs.

Condition or disease Intervention/treatment Phase
Venous Leg Ulcer Procedure: Cyanoacrylate closure Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cyanoacrylate Closure for Treatment of Venous Leg Ulcers
Actual Study Start Date : September 1, 2019
Estimated Primary Completion Date : May 18, 2022
Estimated Study Completion Date : May 18, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cyanoacrylate closure
Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
Procedure: Cyanoacrylate closure
Cyanoacrylate glue embolization targeting venous insufficiency

Primary Outcome Measures :
  1. Rate of adverse events [ Time Frame: 3 months ]
  2. Healing rate [ Time Frame: 3 months ]
    Change in ulcer size

Secondary Outcome Measures :
  1. Rate of adverse events [ Time Frame: 12 months ]
  2. Healing rate [ Time Frame: 12 months ]
    Change in ulcer size

  3. Closure rate [ Time Frame: 12 months ]
    Time to ulcer closure

  4. Patient-reported quality of life: EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire [ Time Frame: 12 months ]
    EuroQol Five Dimension Scale: EQ-5D-5L Health Questionnaire - measures patient-reported health related to five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses for each parameter are coded 1-5, with a lower score reflecting better health, and a higher score meaning worse health. Overall health is self-rated on a scale 0-100, with 0 meaning the worst and 100 meaning the best health imaginable.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥18 years old at time of screening;
  2. Venous leg ulcer;
  3. Venous insufficiency (>0.5 seconds; confirmed by Doppler within last 6 months);
  4. ABI of ≥0.9;
  5. Capable of understanding the study and providing informed consent.

Exclusion Criteria:

  1. Previous hypersensitivity reactions to the VenaSealTM adhesive or cyanoacrylates;
  2. Acute superficial thrombophlebitis;
  3. Bilateral treatment
  4. Thrombophlebitis migrans;
  5. Deep venous thrombosis;
  6. Deep venous incompetence or occlusion in external iliac or distal veins in the affected extremity (as assessed based on spontaneity, phasicity, augmentation, pulsatility, and compressibility on ultrasound);
  7. Post-thrombotic syndrome;
  8. Acute sepsis;
  9. Coagulation disorders;
  10. Radiation or chemotherapy within 3 months of study;
  11. Pregnant or lactating females;
  12. Uncontrolled diabetes (HbA1c >10%);
  13. Diabetic foot ulcers;
  14. Current use of systemic anticoagulation;
  15. Previous treatment of target vein;
  16. Tortuous veins;
  17. Current participation in another interventional study, or participation within 30 days prior to screening;
  18. Inability to tolerate compression, or to receive endovenous treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04011371

Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Medtronic Vascular
Publications of Results:

Layout table for additonal information
Responsible Party: Sunnybrook Health Sciences Centre Identifier: NCT04011371    
Other Study ID Numbers: 424-2017
First Posted: July 8, 2019    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicose Ulcer
Leg Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Varicose Veins
Vascular Diseases
Cardiovascular Diseases